Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Disability progression in aggressive multiple sclerosis.
The role of appraisal and coping style in relation with societal participation in fatigued patients with multiple sclerosis: a cross-sectional multiple mediator analysis.
Successive pregnancies in multiple sclerosis.
Context-Specific Function of S6K2 in Th Cell Differentiation.
The diagnostic accuracy of chromatic pupillary light responses in diseases of the outer and inner retina.
Treatment with NAD(+) inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice.
Gut microflora and multiple sclerosis.
Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis.
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Acute disseminated encephalomyelitis following Plasmodium vivax malaria.
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
Current Evidence Does Not Support Exercise Therapy for Perceived Fatigue in Multiple Sclerosis.
The role of α4 integrin in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease: an infectious animal model for multiple sclerosis (MS).
Neonatal Bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice.
High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud.
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
New insights into the management of patients with autoimmune diseases or inflammatory disorders during pregnancy.
Increasing incidence of multiple sclerosis among women in Buenos Aires: a 22 year health maintenance organization based study.
Reprogramming A375 cells to induced‑resembled neuronal cells by structured overexpression of specific transcription genes.
Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.
Neurorestorative Responses to Delayed Human Mesenchymal Stromal Cells Treatment of Stroke in Type 2 Diabetic Rats.
Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.
Pages
« first
‹ previous
…
824
825
826
827
828
829
830
831
832
…
next ›
last »